Professor Andrea Alimonti is the Director of the Institute of Oncology Research (IOR) and head of the Molecular Oncology Group at the Università della Svizzera italiana and ETH Zurich. He earned his MD from the University of Rome 'La Sapienza' and specialized in oncology at the National Cancer Institute of Rome. Following a postdoctoral fellowship in cancer biology at Memorial Sloan-Kettering Cancer Center and Harvard Medical School, he joined IOR in 2010. Alimonti's research includes therapeutic strategies leveraging cellular senescence and immune responses against tumors, alongside the study of myeloid-derived suppressor cells in prostate cancer progression. His work aims to innovate cancer treatment, with several strategies currently undergoing clinical trials.
Institute of Oncology Research (IOR) • Bellinzona
Leading the Institute of Oncology Research and the Molecular Oncology Group, focusing on innovative cancer therapies.